Detail akcie Belite Bio ADR online

Business Summary: Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Belite Bio Inc (ADR) revenues was not reported. Net loss increased 51% to $39.3M. Higher net loss reflects General and administrative increase from $5.9M to $15.6M (expense), Research and development increase of 20% to $27.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.86 to -$1.23.